Please assess the completion status of the following clinical trial:

Trial Title: Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age 18 and older~* Chronic kidney disease~* Must be able to do stress test~Exclusion Criteria:~* Must not be mentally disabled~* Unable to provide informed consent~* Unable or unwilling to comply with study protocol or procedures~* Pregnancy or unknown pregnancy status in female of childbearing potential~* Participation in any drug trial during the study period~* Prior enrollment in this study~* Active liver disease~* Currently on β-blocker medication at the time of enrollment~* Known history of asthma exacerbation with β-blocker therapy~* Second or third degree AV nodal block or bradycardia with resting heart rate \<50 bpm~* Prior allograft organ transplantation~* Planned allograft transplantation reasonably foreseen within the active treatment period~* Electrocardiographic left or right bundle branch block~* Permanent implanted pacemaker~* Atrial fibrillation~* Ongoing treatment with any of the following medications: sotalol (Betapace), azimilide (Stedicor), quinidine (Quinidex), disopyramide (Norpace), dofetilide (Tikosyn), ibutilide (Corvert), procainamide (Procanbid), bepridil (Vascor), amiodarone (Cordarone), clarithromycin (Biaxin), erythromycin (Eryc), halofantrine (Halfan), pentamidine (Pentam), sparfloxacin (Zagam), domperidone (Motilium), droperidol (Inapsine), chlorpromazine (Thorazine), haloperidol (Haldol), mesoridazine (Serentil), thioridazine (Mellaril), pimozide (Orap), arsenic trioxide (Trisenox), cisapride (Propulsid), lidoflazine (Clinium), and methadone (Dolophine)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All Study Participants (Type: ACTIVE_COMPARATOR): All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.

Based on this trial design, predict the completion outcome and termination type (if applicable).